Canary Cry News Talk cover image

PLANE REPTILIAN MARBLES

Canary Cry News Talk

00:00

Tesla's Commitment to China's Core Socialist Values

Moderna in February forecast a possible net loss for 2023, calling it a transition year before it starts to see sales from experimental vaccines or respiratory since it's an essential. It opened up an office in Hong Kong last year as part of an Asia expansion. Its expansion into mainland China comes as its revenue growth slows sharply due to waning global demand for its COVID-19 vaccine. The US company's only approved product. This is exclusively for the Chinese people and it's going to involve Moderna's mRNA technology - which is interesting because China didn't want any Western vaccines in their citizens prior to this during the pandemic.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app